Buy Tesofensine 500mcg x30 Capsules

▸The Triple Monoamine Reuptake Inhibitor

Tesofensine was originally developed for Parkinson's and Alzheimer's disease, where it incidentally produced dramatic weight loss in clinical trial participants — leading to its redevelopment as an obesity treatment. As a serotonin-dopamine-norepinephrine reuptake inhibitor (SNDRI), it raises monoamine levels in hypothalamic appetite centers, producing powerful appetite suppression that exceeds sibutramine (which only inhibits two transporters) without the cardiovascular side effects that led to sibutramine's withdrawal.

▸Phase II Clinical Data

In the Phase IIb TIPO-1 trial, tesofensine 0.5mg daily produced 10.6% body weight loss over 24 weeks in obese patients — more than double the 4.5% loss seen with sibutramine and significantly exceeding other centrally-acting appetite suppressants. The mechanism of triple monoamine elevation in the hypothalamus produces sustained appetite reduction that many patients describe as a complete loss of food preoccupation.

▸Central vs. Peripheral Approach

Tesofensine's purely central mechanism contrasts with GLP-1 agonists' peripheral gut-based action, making them highly complementary. While GLP-1 agents slow gastric emptying and modulate gut hormones, tesofensine directly modulates the central reward circuitry and appetite centers — addressing the behavioral and neurochemical aspects of overconsumption that gut-focused agents cannot fully address.